Navigation Links
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
Date:5/26/2009

200 and 400 mg/day experienced a median percent reduction in seizure frequency per 28 days of 33.3% and 36.8%, respectively, versus only 18.4% reduction in the placebo group. Additionally, 34.1% and 39.7% of patients taking Vimpat at 200 and 400 mg/day, respectively, experienced greater than or equal to 50% reduction in seizure frequency versus only 22.6% in the placebo group.

Patients randomized to Vimpat(R) also experienced improvement in seizure freedom rates, compared with placebo. Across the pivotal trials, 3.3% of patients randomized to 400 mg/day of Vimpat(R) were seizure free throughout the 12-week maintenance phase, vs. 0.9% of placebo patients. Seizure free days increased by 8% with 200 mg/day of Vimpat(R) and by 12% with 400 mg/day of Vimpat(R), compared with 6% for placebo.

Patients began experiencing a reduction in seizures during the titration phase and maintained or had improved seizure control throughout the studies. The most common adverse events (>10 percent in the Vimpat(R)-treated group and greater than placebo) reported in these trials included dizziness, headache, nausea, and diplopia. More than half of the patients completing the clinical trials opted to continue treatment, some for longer than five years.

Vimpat(R) demonstrated efficacy and tolerability when combined with a broad range of existing AEDs, and also provided efficacy regardless of the number of concomitant AEDs. Vimpat was also studied with several commonly used medications, including digoxin, metformin, omeprazole, and an oral contraceptive (containing 0.03 mg ethinylestradiol and 0.15 mg levonorgetstrel).

Vimpat(R) dosing should start at 50 mg twice daily and may be increased to a daily dose of 200 to 400 mg per day (recommended therapeutic dosing) administered in two divided doses. Vimpat(R) is available as oral tablets and as an intravenous (IV) infusion to allow for consistent treatment in an emergency r
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  The Alabama Supreme Court, ... patients can sue drug makers who mislead doctors into believing ... side‑effects.  The case is Weeks v. Wyeth, and the decision ... in that same case last year. Heninger Garrison Davis attorneys ... the patient in the case, Danny Weeks . ...
(Date:8/19/2014)... 2014 Minimally Invasive Devices Inc. (MID), a ... announced today that Mitsubishi Corporation has formally agreed to ... in Japan . MID anticipates that ... Japan in the second half of 2015. ... for Karl Storz GMBH & Co. (endoscopic instruments and ...
(Date:8/19/2014)...  As power morcellator lawsuits continue to mount ... notes that women in need of fibroid removal ... options that do not involve the use of ... report published by The Wall Street Journal on ... mini-laparotomy and vaginal hysterectomy. Non-surgical options for shrinking ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today ... credit facilities of its wholly owned subsidiary Valeant ... by the Company.  The proposed $1.7 billion senior ... a $200 million revolving facility and a $1.5 ...
... 20, 2011 – Ingenuity® Systems, a leading ... life science researchers, today announced the addition ... from miRecords , plus thousands of ... peer-reviewed literature. The newly added content supplements ...
Cached Medicine Technology:Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2Ingenuity Announces New Additional MicroRNA Content to Complement First-of-its-Kind MicroRNA Filtering Capability in IPA 2
(Date:8/19/2014)... Merrick, NY (PRWEB) August 19, 2014 In honor ... helping you care for your old furry friend by offering tips ... to rely on their owners more. Because of this, dog owners ... for them. , As dogs age, their needs change. They will ... outside as much as they used to. Because of this, pet ...
(Date:8/19/2014)... Following the completion of a $16 million rooms ... is proud to debut the highly anticipated final phase of ... revamp of all public spaces to match the fresh look ... all-new dining experience at 1823 Kitchen and Bar and an ... introduction of 1823 Kitchen and Bar, Grand Hyatt Tampa Bay ...
(Date:8/19/2014)... cannot smoke during their stay and could use this time ... stay smoke-free after returning home. Now a study published ... a program that increased the proportion of hospitalized smokers who ... The system used interactive voice response technology automated ... three months after smokers left the hospital. , ...
(Date:8/19/2014)... 2014 Warfarin, the longtime standard treatment for ... in the anticoagulant drug marketplace including dabigatran, rivaroxaban, ... adoption of these novel oral anticoagulants (NOACs) into ... of all new anticoagulant prescriptions yet this represents ... published in The American Journal of Medicine ...
(Date:8/19/2014)... York, New York (PRWEB) August 19, 2014 ... U.S. courts, Bernstein Liebhard LLP notes the publication of ... antipsychotic medications may increase the risk of acute kidney ... by The Ottawa Citizen, the study was conducted by ... Ont., and the Institute for Clinical Evaluative Sciences, and ...
Breaking Medicine News(10 mins):Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Extended support helps patients stay smoke-free after hospital discharge 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 2Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 4
... , LOS ANGELES, July 28 Interested ... musician? California Cryobank (CCB) , the nation,s leading ... feature, which allows clients to view online photos of celebrities ... "The number one client question we get is ,Who does ...
... for Eligard(R) Sales and Adjusted EBITDA , , VANCOUVER, ... ; TSX: QLT) ("QLT" or the "Company") today reported financial ... specified otherwise, all amounts are in U.S. dollars and in ... another strong financial quarter, with robust Eligard(R) sales of $67.6 ...
... , , CINCINNATI, July 28 ... laser vision correction services under the Lasik Plus ((R)) brand, today ... ended June 30, 2009. , , Second ... the second quarter of 2008) , , ...
... , Nasdaq-Listed Biopharmaceutical Company Focusing ... to Benefit Underserved Patient Populations , , ... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin ... TPTX ), today announced that they have entered into a ...
... , , GAINESVILLE, Fla., ... its stance on electronic cigarette products last week, the administration only tested ... brands is that they are made by the two manufacturers currently suing ... "In comparison to the toxins and carcinogens contained in tobacco ...
... WILMINGTON, Delaware, July 28 According to a new ... ( http://www.marketsandmarkets.com ), the total drug-device,combination market is expected to ... market will account for nearly 30.9% of the total revenues.,The ... from 2009 to 2014. , Browse ...
Cached Medicine News:Health News:California Cryobank Introduces Celebrity Look-a-Likes for Sperm Donors 2Health News:QLT Announces Second Quarter Results for 2009 2Health News:QLT Announces Second Quarter Results for 2009 3Health News:QLT Announces Second Quarter Results for 2009 4Health News:QLT Announces Second Quarter Results for 2009 5Health News:QLT Announces Second Quarter Results for 2009 6Health News:QLT Announces Second Quarter Results for 2009 7Health News:QLT Announces Second Quarter Results for 2009 8Health News:QLT Announces Second Quarter Results for 2009 9Health News:QLT Announces Second Quarter Results for 2009 10Health News:QLT Announces Second Quarter Results for 2009 11Health News:QLT Announces Second Quarter Results for 2009 12Health News:QLT Announces Second Quarter Results for 2009 13Health News:QLT Announces Second Quarter Results for 2009 14Health News:QLT Announces Second Quarter Results for 2009 15Health News:QLT Announces Second Quarter Results for 2009 16Health News:QLT Announces Second Quarter Results for 2009 17Health News:LCA-Vision Reports Second Quarter Financial Results 2Health News:LCA-Vision Reports Second Quarter Financial Results 3Health News:LCA-Vision Reports Second Quarter Financial Results 4Health News:LCA-Vision Reports Second Quarter Financial Results 5Health News:LCA-Vision Reports Second Quarter Financial Results 6Health News:LCA-Vision Reports Second Quarter Financial Results 7Health News:LCA-Vision Reports Second Quarter Financial Results 8Health News:LCA-Vision Reports Second Quarter Financial Results 9Health News:LCA-Vision Reports Second Quarter Financial Results 10Health News:LCA-Vision Reports Second Quarter Financial Results 11Health News:LCA-Vision Reports Second Quarter Financial Results 12Health News:LCA-Vision Reports Second Quarter Financial Results 13Health News:LCA-Vision Reports Second Quarter Financial Results 14Health News:Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement 2Health News:Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement 3Health News:Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement 4Health News:Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement 5Health News:Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement 6
... The Brasseler USA™ Battery Packs contain ... age have a great impact upon battery ... is necessary. Any deviation from these recommendations ... are sensitive to heat. Any exposure of ...
Pneumatic High-speed Drill, Throttleless, 90k Rpm, Microaire Connector....
Pneumatic foot surgical oscillating saw, 24k cpm, available with various hose connector styles....
... Motor Module, without throttle (MicroAire hose connector). ... attachments., ,1050-100 model requires 10ft. ... MicroAire connector. Also requires 9100-000 Foot Control ... hose 9013-000, or existing hose with Linvatec/Hall ...
Medicine Products: